liyi Yu

Dr. liyi Yu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LYliyi Yu
liyi Yu
ZXZhaochun Xu
Zhaochun Xu
MCMeiling Cheng
Meiling Cheng
WLWeizhong Lin
Weizhong Lin
WQWangren Qiu
Wangren Qiu
XXXuan Xiao
Xuan Xiao
A norm in modern medicine is to prescribe polypharmacy to treat disease. The core concern with the co-administration of drugs is that it may produce adverse drug—drug interaction (DDI), which can cause unexpected bodily injury. Therefore, it is essential to identify potential DDI. Most existing methods in silico only judge whether two drugs interact, ignoring the importance of interaction events to study the mechanism implied in combination drugs. In this work, we propose a deep learning framework named MSEDDI that comprehensively considers multi-scale embedding representations of the drug for predicting drug—drug interaction events. In MSEDDI, we design three-channel networks to process biomedical network-based knowledge graph embedding, SMILES sequence-based notation embedding, and molecular graph-based chemical structure embedding, respectively. Finally, we fuse three heterogeneous features from channel outputs through a self-attention mechanism and feed them to the linear layer predictor. In the experimental section, we evaluate the performance of all methods on two different prediction tasks on two datasets. The results show that MSEDDI outperforms other state-of-the-art baselines. Moreover, we also reveal the stable performance of our model in a broader sample set via case studies.

7 December 2023 in Computers in Biology and Medicine
Verified
Journal Article
Open access
LYliyi Yu
liyi Yu
ZXZhaochun Xu
Zhaochun Xu
WQWangren Qiu
Wangren Qiu
XXXuan Xiao
Xuan Xiao
Unexpected side effects may accompany the research stage and post-marketing of drugs. These accidents lead to drug development failure and even endanger patients' health. Thus, it is essential to recognize the unknown drug-side effects. Most existing methods in silico find the answer from the association network or similarity network of drugs while ignoring the drug-intrinsic attributes. The limitation is that they can only handle drugs in the maturation stage. To be suitable for early drug-side effect screening, we conceive a multi-structural deep learning framework, MSDSE, which synthetically considers the multi-scale features derived from the drug. MSDSE can jointly learn SMILES sequence-based word embedding, substructure-based molecular fingerprint, and chemical structure-based graph embedding. In the preprocessing stage of MSDSE, we project all features to the abstract space with the same dimension. MSDSE builds a bi-level channel strategy, including a convolutional neural network module with an Inception structure and a multi-head Self-Attention module, to learn and integrate multi-modal features from local to global perspectives. Finally, MSDSE regards the prediction of drug-side effects as pair-wise learning and outputs the pair-wise probability of drug-side effects through the inner product operation. MSDSE is evaluated and analyzed on benchmark datasets and performs optimally compared to other baseline models. We also set up the ablation study to explain the rationality of the feature approach and model structure. Moreover, we select model partial prediction results for the case study to reveal actual capability. The original data are available at http://github.com/yuliyi/MSDSE.

Verified
Journal Article
Open access
PDF file
XCXiang Cheng
Xiang Cheng
MCMeiling Cheng
Meiling Cheng
LYliyi Yu
liyi Yu
XXXuan Xiao
Xuan Xiao
Adverse drug reactions (ADRs) are a major issue to be addressed by the pharmaceutical industry. Early and accurate detection of potential ADRs contributes to enhancing drug safety and reducing financial expenses. The majority of the approaches that have been employed to identify ADRs are limited to determining whether a drug exhibits an ADR, rather than identifying the exact type of ADR. By introducing the “multi-level feature-fusion deep-learning model”, a new predictor, called iADRGSE, has been developed, which can be used to identify adverse drug reactions at the early stage of drug discovery. iADRGSE integrates a self-attentive module and a graph-network module that can extract one-dimensional sub-structure sequence information and two-dimensional chemical-structure graph information of drug molecules. As a demonstration, cross-validation and independent testing were performed with iADRGSE on a dataset of ADRs classified into 27 categories, based on SOC (system organ classification). In addition, experiments comparing iADRGSE with approaches such as NPF were conducted on the OMOP dataset, using the jackknife test method. Experiments show that iADRGSE was superior to existing state-of-the-art predictors.

28 September 2024 in Biology
Verified
Journal Article
Open access
PDF file
LZLuo Zhengtao
Luo Zhengtao
LYliyi Yu
liyi Yu
ZXZhaochun Xu
Zhaochun Xu
KLKening Liu
Kening Liu
LGLichuan Gu
Lichuan Gu
N6-methyladenosine (m6A) plays a crucial regulatory role in the control of cellular functions and gene expression. Recent advances in sequencing techniques for transcriptome-wide m6A mapping have accelerated the accumulation of m6A site information at a single-nucleotide level, providing more high-confidence training data to develop computational approaches for m6A site prediction. However, it is still a major challenge to precisely predict m6A sites using in silico approaches. To advance the computational support for m6A site identification, here, we curated 13 up-to-date benchmark datasets from nine different species (i.e., H. sapiens, M. musculus, Rat, S. cerevisiae, Zebrafish, A. thaliana, Pig, Rhesus, and Chimpanzee). This will assist the research community in conducting an unbiased evaluation of alternative approaches and support future research on m6A modification. We revisited 52 computational approaches published since 2015 for m6A site identification, including 30 traditional machine learning-based, 14 deep learning-based, and 8 ensemble learning-based methods. We comprehensively reviewed these computational approaches in terms of their training datasets, calculated features, computational methodologies, performance evaluation strategy, and webserver/software usability. Using these benchmark datasets, we benchmarked nine predictors with available online websites or stand-alone software and assessed their prediction performance. We found that deep learning and traditional machine learning approaches generally outperformed scoring function-based approaches. In summary, the curated benchmark dataset repository and the systematic assessment in this study serve to inform the design and implementation of state-of-the-art computational approaches for m6A identification and facilitate more rigorous comparisons of new methods in the future.